Skip to content
MARKETS / BALCAO / ETST
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Earth Science Tech, Inc. ETST

14 fiscal years on record · USD · FY2025 reported · SEC filings only
$35.7M
▲ 7.8% YoY
$3.6M
▲ 11.6% YoY
$1.2M
▼ 67.3% YoY
In brief

What this company does

ETST operates as a diversified holding company focused on the health and wellness sector. The Company’s principal operating strategy is to build a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms, clinical support, and patient fulfillment. Our pharmacy subsidiaries, RxCompound and Mister Meds are primarily governed by Section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA). As of March 31, 2026, the Company has 77 employees.

Written from the business description in Earth Science Tech, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 18 June 2026. Every sentence was checked against that document before publication.

Growth
USD 35.7M
Revenue, FY2025 · full 14-year series below
Revenue $M Net income $M
FY2025 · Revenue 35.7 · Net income 3.6
20M-5M-10M20102012201420182020202220242025
Compound annual growth
+802.6%
+202.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +202.5% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
10 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 8.7% · Net 10.1%
10000%20000%-50000%-100000%-150000%20102012201420182020202220242025
ROE
FY2025 · ROE 66.9%
-1000%-2000%-3000%20102012201420182020202220242025

Each USD of equity produced 67 cents of profit this year.

Cash & shareholders
USD 471,410.00
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 1.2
2.0M-0.2M-0.4M20102012201420182020202220242025
Net buybacks $M Dividends $M
FY2025 · Dividends — · Net buybacks 0.5
0.5M1.0M202320242025

USD 471,410.00 in buybacks — 13% of the year's profit went back to shareholders.

Total assetsUSD 9.0M
EquityUSD 7.0M
CashUSD 796,797.00
Current ratio1.93×

Equity funds 78% of total assets.

The 14-year record
14 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720142013201220112010
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.0·
Operating income $B0.00.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0·
EBITDA $B0.00.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0····
Income tax $B−0.00.00.0········0.00.0·
Net income $B0.00.00.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B0.00.00.0······−0.0····
EPS, diluted $0.010.010.00−0.00·−0.08−0.03−0.04−0.04−0.23−1.17−0.010.00·
Dividend / sh $··············
Payout %··············
ROE %66.9106.748.2······−1324.3−3943.2···
Shares out B0.290.290.310.280.050.050.040.050.050.040.040.010.01·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 61 reconciliationsAUDITED

Reconciled in 14 of 19 fiscal years. 34 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inFlorida
Fiscal year endsMarch 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image